Alachkar, Nada http://orcid.org/0000-0003-1249-2455
Li, Jing
Matar, Dany
Vujjini, Vikas
Alasfar, Sami
Tracy, Melissa
Reiser, Jochen
Wei, Changli
Funding for this research was provided by:
Terumo BCT
National Institutes of Health (R01DK101350, R01DK101350, R01DK101350)
Article History
Received: 14 June 2018
Accepted: 5 December 2018
First Online: 17 December 2018
Ethics approval and consent to participate
: This work was approved by the institutional review board (IRB) of Johns Hopkins Hospital. Written consents were obtained from the participates in the prospective study.
: Not applicable
: At the time of publication, NA is a Section Editor at BMC Nephrology.CW has a pending patent on suPAR in diabetic kidney disease. JR is cofounder and stockholder of Trisaq, a biotechnological company developing novel therapeutics for chronic kidney diseases and FSGS. He has pending and issued patents in the therapeutic and diagnostic space regarding kidney diseases.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.